ATOPIC DERMATITIS

This study tests a drug called lebrikizumab, given alone or with steroid creams, for people with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it safely reduces skin redness, itching, and rash. About 301 adults took part, and the study is now active but not…

This study follows 50 people with hand eczema who are starting treatment with methotrexate, a medicine often used for arthritis and other skin conditions. Researchers want to see how well it controls eczema symptoms and improves quality of life, and to track any side effects or r…

This study looks at whether people with well-controlled atopic dermatitis (eczema) can safely take dupilumab less often without losing control of their disease. About 256 teens and adults who have been on the standard every-2-week dose for at least a year will either stay on that…

This study tests an experimental drug called Afimkibart (RO7790121) in 160 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it improves skin symptoms like redness and itching better than a placebo. Participants receive the drug or placebo for sever…

This study tests whether an experimental drug called TRIV-509 can help adults with moderate to severe atopic dermatitis (a type of eczema). About 95 participants will receive either TRIV-509 or a placebo for 16 weeks, then switch to the other treatment. The goal is to see if the …

This study tests whether the drug baricitinib is safe and effective for children and teenagers (ages 2 to 17) with moderate to severe eczema that hasn't improved with standard creams. About 516 participants will receive either baricitinib or a placebo pill. The goal is to see if …

This study looks at how well upadacitinib (RINVOQ) controls moderate to severe atopic dermatitis (eczema) over two years in everyday medical practice. About 772 teens and adults in Germany will take the drug as prescribed by their doctor. Researchers will track symptom control an…

This study is checking the long-term safety of a drug called rocatinlimab for people with moderate-to-severe eczema (atopic dermatitis). It involves over 2,600 adults and teens who have already completed a previous rocatinlimab study. Researchers will monitor side effects and see…

This study tests whether a new combination of two drugs (APG777 and APG990) is safe and how the body processes them in adults with moderate-to-severe atopic dermatitis (eczema). About 86 participants will receive either the new combo or an existing treatment (dupilumab) for 24 we…

This study tests an experimental drug called GIA632 in adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it safely clears or nearly clears the skin compared to a placebo. About 34 participants will receive either the drug or a placebo, and results w…

This study tests an experimental drug called TQH2722 for adults with moderate to severe eczema (atopic dermatitis). About 500 people will receive either the drug or a placebo to see if it safely reduces skin redness, itching, and rash. The goal is to improve quality of life by co…

This study tests an oral medication called jaktinib for adults with moderate to severe atopic dermatitis (eczema). About 443 participants will receive either jaktinib or a placebo to see if it improves skin symptoms like redness and itching. The goal is to reduce eczema severity …

This study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). Participants who completed a prior study can join this extension, which lasts about 68 weeks (or up to 116 w…

This study tests whether a daily pill called upadacitinib, when used with a steroid cream, can safely reduce eczema symptoms like itching and skin redness. About 1,500 teens and adults with moderate-to-severe eczema who need stronger treatment took part. The main goal was to see …

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. The goal is to see if it safely reduces skin r…

This study tests a new drug called CM310 in 180 teenagers with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug is safe and helps clear the skin. Participants receive the drug for several weeks, and doctors track side effects and skin improvement.

This study looks at how safe and effective the medicine CIBINQO is for treating atopic dermatitis (a type of eczema) in real-world Japanese medical practice. About 1,128 people are taking part. Researchers are tracking side effects and how well the drug clears skin symptoms.

This study tests whether the drug upadacitinib, taken as a pill along with steroid creams, can safely improve moderate-to-severe eczema in children aged 2 to 11 in Japan. About 99 children will be randomly assigned to receive either the drug or a placebo for 12 weeks, then all wi…

This study tests a drug called lebrikizumab in children aged 6 months to under 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it reduces skin redness, itching, and rash better than a placebo. About 367 participants will receive either the drug …

This study tests whether starting a special skin care routine early in life can prevent food allergies in babies who already have eczema. About 400 infants with eczema by 12 weeks old will either get proactive treatment (a barrier cream and a steroid cream) or standard care. The …

This study tests an experimental drug called ATI-045 against a placebo in 110 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if the drug can reduce skin redness, swelling, and itching over 24 weeks. Participants must have had eczema for at least 6 m…

This study tests whether adding narrowband UVB phototherapy (a type of light treatment) to standard topical creams works better than creams alone for adults with moderate atopic eczema. About 316 participants will be randomly assigned to receive either 8-16 weeks of UVB plus opti…

This study tests an experimental drug called APG777 in 470 adults with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…

This study tests a gel called HY209 in 210 adults with mild to moderate atopic dermatitis (eczema). The gel is applied to the skin to see if it reduces redness, itching, and rash. Half the participants get the real gel, half get a placebo, and neither they nor the doctors know wh…

This study tests an experimental daily pill (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis) who have not found a suitable prescription treatment. About 200 participants will take either the study drug or a placebo for 12 weeks, and researchers will tra…

This study tested whether Bodewell eczema products are safe and effective for treating atopic dermatitis, a common skin condition. Fifteen adults used the products for 12 weeks. Researchers measured skin improvement and quality of life changes. The goal was to see if these over-t…

This study tests an investigational drug called barzolvolimab in adults with moderate to severe atopic dermatitis (eczema). About 131 participants will receive either a low dose, high dose, or placebo to see if it reduces itching and clears skin over 16 weeks. The goal is to find…

This early study tests a special microbubble bath (Thera-Clean) that uses no chemicals to clean skin, reduce itch, and help wounds heal. About 20 people aged 2 and older with epidermolysis bullosa, ichthyosis, atopic dermatitis, or psoriasis will use the bath at home for 8 weeks.…

This early-stage study tests a new ointment called CU-10101 in 64 people—first in healthy volunteers, then in those with mild-to-moderate atopic dermatitis (eczema). The main goal is to check safety and how the body handles the ointment, not yet to prove it works. Participants ar…

This study follows 143 children aged 6 months to 11 years with severe atopic dermatitis (eczema) in Spain who are starting treatment with dupilumab. Researchers will observe how the drug is used in real-world clinics, its effectiveness, and any side effects over two years. No ext…

This study is creating a large registry of up to 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants over time to see how treatments work in everyday medical practice and track any side effects. T…

This study looks at how a new medicine called PF-08049820, being developed for eczema, changes the way other drugs work in the body. Researchers will give healthy women birth control pills, a sedative, and a blood thinner, both with and without PF-08049820, to measure differences…

This study follows 456 mothers and their children for five years to see if certain chemicals in the mother's blood during pregnancy are linked to the child developing eczema. Researchers will check children's skin and track any eczema diagnosis. The goal is to understand possible…

This study follows 10,000 adults with atopic dermatitis (eczema) to see how well approved treatments work and how safe they are in everyday medical practice. Researchers will also track the disease's natural history, related health problems, and current treatment patterns. Partic…

This study aims to better understand the immune response in the blood of people with atopic dermatitis (eczema). Researchers will collect blood samples from about 30 adults with moderate to severe eczema and stimulate the blood with immune triggers to measure cytokine levels. The…

This study follows 8,000 children aged 2 to 17 with eczema who have used Elidel cream. Researchers are monitoring them for 10 years to see if the cream increases the risk of cancer. No new treatment is given—this is an observational registry to gather safety data.

This study follows 2,500 children from before birth up to age 3 (or 6) to learn what causes food allergies and eczema. Researchers collect samples and health information to find early warning signs and biological pathways. The goal is to better understand and predict these condit…

This early-stage study tests how a new drug (SHR-1819) enters the body when injected with different devices. It involves 160 healthy adults aged 18-55. The goal is to compare the drug's absorption and safety across devices, not to treat any disease.

This study looks at gene changes (filaggrin mutations) in 300 Latinx adults with eczema. Researchers want to see if these mutations are linked to more severe or different disease patterns. The goal is to better understand the condition in this group, not to test a new treatment.

This study looks at skin and blood samples from 505 children with eczema (atopic dermatitis) to find biological markers that explain the disease. Researchers compare these markers to those in adults to better understand what causes eczema in kids. No new treatments are tested; th…